Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;2(5):500-7.
doi: 10.5489/cuaj.916.

Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting

Michael Sia  1 , Tom Pickles, Gerard Morton, Louis Souhami, Himu Lukka, Padraig Warde
Affiliations

Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting

Michael Sia et al. Can Urol Assoc J. 2008 Oct.

Abstract

For patients with recurrent prostate cancer after radical prostatectomy, salvage radiotherapy is the only potentially curative treatment option. However, until recently there has been a paucity of data on the effectiveness of this approach. In light of recently published studies, the Genito-Urinary Radiation Oncologists of Canada (GUROC) met and crafted a consensus statement regarding the current place of salvage radiotherapy. GUROC also identified gaps in current knowledge and identified ongoing study protocols that will advance our knowledge in this area.This report summarizes the main conclusions of the meeting and the commentary provided during the consensus-building process, and outlines the consensus statement that was subsequently adopted.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Four-year actuarial progression-free probability (PFP) after salvage radiotherapy. ADT = androgen deprivation therapy; PSA = prostate-specific antigen; PSADT = prostate-specific antigen doubling time; RT = radiotherapy. Adapted with permission from Stephenson AJ, Shariat SF, Zelefsky MJ, et al. (JAMA 2004;291:1325–1332). (Note: the conversion factor between ng/mL and μg/L is 1.0.)
Fig 2
Fig 2
(A) Kaplan–Meier estimate of the overall progression-free probability after salvage radiotherapy. (B) Progression-free probability after salvage radiotherapy stratified by preradiotherapy prostate-specific antigen level ≤ 0.50 μg/L (blue), 0.51–1.00 μg/L (yellow), 1.01–1.50 μg/L (grey) and > 1.50 μg/L (red). Adapted with permission from Stephenson AJ, Scardino PT, Kattan MW, et al. (J Clin Oncol 2007;25:2035–41).
Fig 3
Fig 3
Schema of the NCIC-CTG PR.13 randomized trial. HT = hormone therapy; PSA = prostate-specific antigen; RT = radiotherapy.
See this image and copyright information in PMC

Comment in

  • Can Urol Assoc J. 2:508.

References

    1. Grossfeld GD, Stier DM, Flanders SC, et al. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol. 1998;160:1398–404. - PubMed
    1. Pickles T, Morgan S, Morton G, et al. Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement. CUAJ. 2008;2:95–9. - PMC - PubMed
    1. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163:1632–42. - PubMed
    1. Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395–406. - PubMed
    1. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–23. - PubMed